COPD exacerbations in general practice: variability in oral prednisolone courses

<p>Abstract</p> <p>Background</p> <p>The use of oral corticosteroids as treatment of COPD exacerbations in primary care is well established and evidence-based. However, the most appropriate dosage regimen has not been determined and remains controversial. Corticosteroid...

Full description

Bibliographic Details
Main Authors: de Vries Marianne, Berendsen Annette J, Bosveld Henk EP, Kerstjens Huib AM, van der Molen Thys
Format: Article
Language:English
Published: BMC 2012-01-01
Series:BMC Family Practice
Online Access:http://www.biomedcentral.com/1471-2296/13/3
_version_ 1811223492717182976
author de Vries Marianne
Berendsen Annette J
Bosveld Henk EP
Kerstjens Huib AM
van der Molen Thys
author_facet de Vries Marianne
Berendsen Annette J
Bosveld Henk EP
Kerstjens Huib AM
van der Molen Thys
author_sort de Vries Marianne
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>The use of oral corticosteroids as treatment of COPD exacerbations in primary care is well established and evidence-based. However, the most appropriate dosage regimen has not been determined and remains controversial. Corticosteroid therapy is associated with a number of undesirable side effects, including hyperglycaemias, so differences in prescribing might be relevant. This study examines the differences between GPs in dosage and duration of prednisolone treatment in patients with a COPD exacerbation. It also investigates the number of general practitioners (GPs) who adjust their treatment according to the presence of diabetic co-morbidity.</p> <p>Methods</p> <p>Cross-sectional study among 219 GPs and 25 GPs in training, located in the Northern part of the Netherlands.</p> <p>Results</p> <p>The response rate was 69%. Nearly every GP prescribed a continuous dose of prednisolone 30 mg per day. Among GPs there were substantial differences in treatment duration. GPs prescribed courses of five, seven, ten, or fourteen days. A course of seven days was most common. The duration of treatment depended on exacerbation and disease severity. A course of five days was especially prescribed in case of a less severe exacerbation. In a more severe exacerbation duration of seven to fourteen days was more common. Hardly any GP adjusted treatment to the presence of diabetic co-morbidity.</p> <p>Conclusion</p> <p>Under normal conditions GPs prescribe prednisolone quite uniformly, within the range of the current Dutch guidelines. There is insufficient guidance regarding how to adjust corticosteroid treatment to exacerbation severity, disease severity and the presence of diabetic co-morbidity. Under these circumstances, there is a substantial variation in treatment duration.</p>
first_indexed 2024-04-12T08:34:56Z
format Article
id doaj.art-245bd06b8bba405997963e8059922d2b
institution Directory Open Access Journal
issn 1471-2296
language English
last_indexed 2024-04-12T08:34:56Z
publishDate 2012-01-01
publisher BMC
record_format Article
series BMC Family Practice
spelling doaj.art-245bd06b8bba405997963e8059922d2b2022-12-22T03:40:03ZengBMCBMC Family Practice1471-22962012-01-01131310.1186/1471-2296-13-3COPD exacerbations in general practice: variability in oral prednisolone coursesde Vries MarianneBerendsen Annette JBosveld Henk EPKerstjens Huib AMvan der Molen Thys<p>Abstract</p> <p>Background</p> <p>The use of oral corticosteroids as treatment of COPD exacerbations in primary care is well established and evidence-based. However, the most appropriate dosage regimen has not been determined and remains controversial. Corticosteroid therapy is associated with a number of undesirable side effects, including hyperglycaemias, so differences in prescribing might be relevant. This study examines the differences between GPs in dosage and duration of prednisolone treatment in patients with a COPD exacerbation. It also investigates the number of general practitioners (GPs) who adjust their treatment according to the presence of diabetic co-morbidity.</p> <p>Methods</p> <p>Cross-sectional study among 219 GPs and 25 GPs in training, located in the Northern part of the Netherlands.</p> <p>Results</p> <p>The response rate was 69%. Nearly every GP prescribed a continuous dose of prednisolone 30 mg per day. Among GPs there were substantial differences in treatment duration. GPs prescribed courses of five, seven, ten, or fourteen days. A course of seven days was most common. The duration of treatment depended on exacerbation and disease severity. A course of five days was especially prescribed in case of a less severe exacerbation. In a more severe exacerbation duration of seven to fourteen days was more common. Hardly any GP adjusted treatment to the presence of diabetic co-morbidity.</p> <p>Conclusion</p> <p>Under normal conditions GPs prescribe prednisolone quite uniformly, within the range of the current Dutch guidelines. There is insufficient guidance regarding how to adjust corticosteroid treatment to exacerbation severity, disease severity and the presence of diabetic co-morbidity. Under these circumstances, there is a substantial variation in treatment duration.</p>http://www.biomedcentral.com/1471-2296/13/3
spellingShingle de Vries Marianne
Berendsen Annette J
Bosveld Henk EP
Kerstjens Huib AM
van der Molen Thys
COPD exacerbations in general practice: variability in oral prednisolone courses
BMC Family Practice
title COPD exacerbations in general practice: variability in oral prednisolone courses
title_full COPD exacerbations in general practice: variability in oral prednisolone courses
title_fullStr COPD exacerbations in general practice: variability in oral prednisolone courses
title_full_unstemmed COPD exacerbations in general practice: variability in oral prednisolone courses
title_short COPD exacerbations in general practice: variability in oral prednisolone courses
title_sort copd exacerbations in general practice variability in oral prednisolone courses
url http://www.biomedcentral.com/1471-2296/13/3
work_keys_str_mv AT devriesmarianne copdexacerbationsingeneralpracticevariabilityinoralprednisolonecourses
AT berendsenannettej copdexacerbationsingeneralpracticevariabilityinoralprednisolonecourses
AT bosveldhenkep copdexacerbationsingeneralpracticevariabilityinoralprednisolonecourses
AT kerstjenshuibam copdexacerbationsingeneralpracticevariabilityinoralprednisolonecourses
AT vandermolenthys copdexacerbationsingeneralpracticevariabilityinoralprednisolonecourses